West Nile Virus Seroprevalence Under Bird Ringers

Sponsor
Leiden University Medical Center (Other)
Overall Status
Completed
CT.gov ID
NCT05294003
Collaborator
Erasmus Medical Center (Other), UMC Utrecht (Other), Leiden University (Other), Netherlands Institute of Ecology (Other)
162
1
6.6
24.7

Study Details

Study Description

Brief Summary

In August 2020, West Nile Virus (WNV) was isolated from a live common whitethroat for the first time in The Netherlands. Follow-up sampling showed that the virus could also be detected in mosquitos from the same location during at least a whole month of sampling. On 15 October 2020, one case of West Nile virus infection has been reported in a man who was likely infected in the Utrecht region. This is the first time that a locally acquired human case of WNV infection has been reported in The Netherlands. Six additional cases have been identified, one of which from the region Arnhem. West Nile virus infection is a mosquito-borne zoonosis. The disease, which has spread across the Northern Hemisphere in the past three decades, is now found on an annual basis in many European countries where the centre of gravity lies in Southern-European countries. Recently, WNV was reported for the first time in Germany. The virus is transmitted among birds through the bite of infected mosquitoes and incidentally infects humans and other mammals, such as horses. Around 80% of human WNV infections are asymptomatic. The most common clinical presentation is West Nile fever but, older people and immunocompromised persons are at higher risk of developing neuro-invasive disorders (West Nile neuroinvasive disease). Currently, there are no prophylaxis or specific treatment against the disease in humans. In addition, Usutu virus (USUV) was detected in The Netherlands in 2016. USUV is another flavivirus, related to WNV, and also capable of infecting humans. Disease associated with USUV infection in humans appears to be milder and only limited number of cases have been identified. During their bird catching activities, bird ringers are intensively exposed to mosquito bites at the natural habitat of the birds and at the same time of the day when mosquitoes are particularly active. The aim of this study is therefore to determine the prevalence of WNV and USUV serum antibodies in bird ringers in The Netherlands.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    162 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Prevalence of West Nile Virus and Usutu Virus Serum Antibodies in Dutch Bird Ringers
    Actual Study Start Date :
    May 28, 2021
    Actual Primary Completion Date :
    Sep 22, 2021
    Actual Study Completion Date :
    Dec 14, 2021

    Outcome Measures

    Primary Outcome Measures

    1. The proportion of individuals with neutralising antibodies against WNV by region [One blood sample collected between June and September 2021]

    2. The proportion of individuals with neutralising antibodies against USUV by region [One blood sample collected between June and September 2021]

    Secondary Outcome Measures

    1. The proportion of individuals with IgM antibodies against WNV [One blood sample collected between June and September 2021]

    2. The proportion of individuals with IgG antibodies against WNV [One blood sample collected between June and September 2021]

    3. The proportion of individuals with IgM antibodies against USUV [One blood sample collected between June and September 2021]

    4. The proportion of individuals with IgG antibodies against USUV [One blood sample collected between June and September 2021]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Carrying-out bird ringing activities during spring, summer or early autumn 2020 in The Netherlands
    Exclusion Criteria:
    • Not willing to participate in this study

    • Using medication interfering with antibodies production

    • Under 18 years of age

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Leiden University Medical Centre (LUMC) Leiden Netherlands

    Sponsors and Collaborators

    • Leiden University Medical Center
    • Erasmus Medical Center
    • UMC Utrecht
    • Leiden University
    • Netherlands Institute of Ecology

    Investigators

    • Principal Investigator: Chiara de Bellegarde, LUMC

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    Chiara de Bellegarde, Principal Investigator, Leiden University Medical Center
    ClinicalTrials.gov Identifier:
    NCT05294003
    Other Study ID Numbers:
    • P20.112
    First Posted:
    Mar 24, 2022
    Last Update Posted:
    Mar 24, 2022
    Last Verified:
    Mar 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 24, 2022